- Home
- DOCU vs ABVX Comparison
DOCU vs ABVX Comparison
Compare DOCU & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DOCU | ABVX |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | France |
| Employees | 7044 | 69 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.9B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOCU | ABVX |
|---|---|---|
| Price | $52.60 | $136.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $63.33 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 3.8M | 2.2M |
| Earning Date | 06-04-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $3,219,500,000.00 | N/A |
| Revenue This Year | $10.58 | $52.14 |
| Revenue Next Year | $7.33 | $4,132.27 |
| P/E Ratio | $133.44 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $40.16 | $9.96 |
| 52 Week High | $86.65 | $148.83 |
Technical Indicators
Market Signals| Indicator | DOCU | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 60.02 |
| Support Level | $44.43 | $106.03 |
| Resistance Level | $57.29 | $148.41 |
| Average True Range (ATR) | 1.97 | 5.36 |
| MACD | 0.86 | 0.81 |
| Stochastic Oscillator | 81.03 | 78.92 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.